达罗他胺治疗转移性激素敏感性前列腺癌的疼痛与健康相关生活质量结局(ARANOTE研究二次分析)
ARANOTE是一项国际、随机、双盲、安慰剂对照的3期试验,纳入669例转移性激素敏感性前列腺癌(mHSPC)患者,按2:1随机接受达罗他胺600mg每日两次或安慰剂,均联合雄激素剥夺治疗(ADT)。结合已知生存获益,这些临床有意义的延迟支持达罗他胺联合ADT作为mHSPC的标准治疗选择。
要点
- 安全性方面,常见3-4级不良事件为高血压、贫血和AST升高,严重不良事件发生率两组相似(24% vs 24%)。
核心结论
- 在mHSPC患者中,达罗他胺联合ADT较安慰剂联合ADT延迟疼痛进展并延长总体健康状况恶化时间,结合生存获益支持其作为标准治疗选择。
研究设计与样本
- ARANOTE为国际、随机、双盲、安慰剂对照的3期试验,在15个国家133个癌症中心纳入669例mHSPC男性患者,按2:1随机接受达罗他胺600mg每日两次(n=446)或安慰剂(n=223),均联合ADT。
主要发现
- 最常见的3-4级不良事件为高血压(达罗他胺组19例[4%] vs 安慰剂组8例[4%])、贫血(14例[3%] vs 8例[4%])和天冬氨酸氨基转移酶升高(10例[2%] vs 1例[<1%])。
- 严重不良事件发生率两组均为24%(达罗他胺组105例 vs 安慰剂组52例)。
- 发生1例治疗相关5级事件(报告为死亡,未另作说明)。
关键数值与推荐
- 疼痛进展定义为简要疼痛量表-简表最严重疼痛评分增加≥2分或开始使用阿片类药物≥7天。
- 总体健康状况恶化定义为FACT-P总分下降≥10分。
临床怎么用
- 对于mHSPC患者,达罗他胺联合ADT可考虑作为标准治疗选择,以延缓疼痛进展和总体健康状况恶化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with metastatic hormone-sensitive prostate cancer (mHSPC), darolutamide significantly improved radiological progression-free survival versus placebo (hazard ratio [HR] 0·54, 95% CI 0·41-0·71) in the phase 3 ARANOTE study. In addition to survival, symptom control and health-related quality of life (HRQoL) are important factors in treatment decision making; we therefore report pain, HRQoL, and safety outcomes from the ARANOTE trial. METHODS: ARANOTE is an international, randomised, double-blind, placebo-controlled, phase 3 trial involving men aged 18 years or older, with Eastern Cooperative Oncology Group performance status 0-2 and recurrent or de novo mHSPC, treated at 133 cancer centres in 15 countries. Participants were randomly assigned (2:1) to 600 mg darolutamide or matching placebo orally twice daily, both with investigator's choice of androgen deprivation therapy (ADT; luteinising hormone-releasing hormone agonist or antagonist, or orchiectomy) starting within 12 weeks before randomisation. Randomisation was stratified by presence versus absence of visceral metastases and by previous versus no previous local therapy. Treatment was assigned centrally using an interactive web response system based on a computer-generated permuted block randomisation list with block sizes of six. The investigators, the participants, and the sponsor remained masked to treatment assignment throughout the study. The primary endpoint (reported previously) was radiological progression-free survival. Here, we assessed time to pain progression (≥2-point increase in Brief Pain Inventory-Short Form worst pain score or initiation of opioid for ≥7 days; secondary endpoint) and time to deterioration of overall wellbeing (≥10-point decrease in Functional Assessment of Cancer Therapy-Prostate [FACT-P] total score; prespecified exploratory endpoint). Pain and HRQoL outcomes were analysed in the intention to treat population; safety was analysed in all treated patients according to treatment actually received. The trial, registered at ClinicalTrials.gov, NCT04736199, is ongoing, but no longer recruiting. FINDINGS: Between Feb 23, 2021, and June 14, 2022, 669 patients (all male; 376 [56%] White, 209 [31%] Asian, 65 [10%] Black, 19 [3%] other race) were randomly assigned to receive darolutamide (n=446) or placebo (n=223). At the data cutoff date for the primary analysis (June 7, 2024), the median follow-up duration for the analyses presented here was 22·8 months (IQR 12·3-27·4) in the darolutamide group and 20·3 months (11·4-25·2) in the placebo group. Darolutamide delayed time to pain progression (HR 0·72; 95% CI 0·54-0·96) and extended time to deterioration in FACT-P total score (HR 0·76; 0·61-0·94) versus placebo. The most common grade 3-4 adverse events were hypertension (19 [4%] of 445 patients who received darolutamide vs eight [4%] of 221 patients who received placebo), anaemia (14 [3%] vs eight [4%]), and aspartate aminotransferase increase (ten [2%] vs one [<1%]). Serious adverse events occurred in 105 (24%) versus 52 (24%) patients, respectively. One treatment-related grade 5 event occurred, reported as death (not otherwise specified). INTERPRETATION: Along with the known survival benefits, the clinically meaningful delays in pain progression and time to deterioration of overall wellbeing support consideration of darolutamide plus ADT as a standard-of-care treatment option in patients with mHSPC. FUNDING: Bayer and Orion Pharma.
引用
- Morgans AK, Haresh KP, Jievaltas M, et al. Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2026. PMID: 41969015. doi:10.1016/S1470-2045(26)00014-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。